These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8531414)

  • 1. Antithrombotic effect of TA-993, a novel 1,5-benzothiazepine derivative, in conscious rats.
    Narita H; Kaburaki M; Doi H; Yasoshima A; Murata S
    Jpn J Pharmacol; 1995 Aug; 68(4):397-404. PubMed ID: 8531414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic action of TA-993, a new 1,5-benzothiazepine derivative, in a canine model of femoral arterial thrombosis.
    Kaburaki M; Doi H; Narita H; Odawara A; Yasoshima A; Murata S
    J Cardiovasc Pharmacol; 1998 Mar; 31(3):470-7. PubMed ID: 9514194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effects of TA-993, a new 1,5-benzothiazepine derivative, on platelet aggregation.
    Odawara A; Kikkawa K; Katoh M; Toryu H; Shimazaki T; Sasaki Y
    Circ Res; 1996 Apr; 78(4):643-9. PubMed ID: 8635222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-lasting hypotensive and antihypertensive effects of a new 1,5-benzothiazepine calcium antagonist in hypertensive rats and renal hypertensive dogs.
    Narita H; Murata S; Yabana H; Kikkawa K; Sugawara Y; Akimoto Y; Nagao T
    Arzneimittelforschung; 1988 Apr; 38(4):515-20. PubMed ID: 3041970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet mechanisms of TA-993 and its metabolite MB3 in ADP-induced platelet aggregation.
    Katoh M; Karasawa T; Doi H; Odawara A; Takagi M; Ikeo T; Narita H
    Eur J Pharmacol; 2000 Jul; 399(2-3):91-6. PubMed ID: 10884507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of TA-993, a novel therapeutic agent for peripheral circulatory insufficiency, on skeletal muscle fatigue in a rat model of hindlimb ischemia.
    Doi H; Kaburaki M; Inoue H; Suzumura K; Narita H
    Jpn J Pharmacol; 2000 May; 83(1):73-81. PubMed ID: 10887943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
    Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effect of clentiazem (TA-3090) on platelet aggregation--alone and in combination with aspirin or ticlopidine.
    Odawara A; Katoh M; Karasawa T; Tamura K; Sasaki Y
    Thromb Res; 1994 Jul; 75(2):109-19. PubMed ID: 7974385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the antiplatelet agent TA-993 and its metabolite MB3 on the hemorheological properties of rat and human erythrocytes.
    Katoh M; Karasawa T; Doi H; Odawara A
    Thromb Res; 2001 Oct; 104(2):105-12. PubMed ID: 11672754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mechanism of the increasing action of TA-993, a new 1,5- benzothiazepine derivative, on limb blood flow in anesthetized dogs: selective suppression of sympathetic nerve activity.
    Kaburaki M; Yabana H; Doi H; Nagata K; Narita H; Murata S
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1167-73. PubMed ID: 10027855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents.
    Honda Y; Kamisato C; Morishima Y
    Eur J Pharmacol; 2016 Sep; 786():246-252. PubMed ID: 27288116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
    Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
    J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis biological evaluation of alkyl, alkoxy, alkylthio, or amino-substituted 2,3-dihydro-1,5-benzothiazepin-4(5H)-ones.
    Inoue H; Konda M; Hashiyama T; Otsuka H; Watanabe A; Gaino M; Takahashi K; Date T; Okamura K; Takeda M; Narita H; Murata S; Odawara A; Sasaki H; Nagao T
    Chem Pharm Bull (Tokyo); 1997 Jun; 45(6):1008-26. PubMed ID: 9214707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous and oral antiplatelet/antithrombotic efficacy and specificity of XR300, a novel nonpeptide platelet GPIIb/IIIa antagonist.
    Mousa SA; Forsythe M; Wityak J; Bozarth J; Mu DX
    J Cardiovasc Pharmacol; 1998 Mar; 31(3):441-8. PubMed ID: 9514190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
    Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
    Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic activity of NSP-513, a novel selective phosphodiesterase 3 inhibitor, on femoral arterial thrombosis induced by physical stenosis and electrical current: comparison of antithrombotic and hemodynamic effects.
    Hirose H; Mashiko S; Kimura T; Ishida F; Mochizuki N; Nishibe T; Nishikibe M
    J Cardiovasc Pharmacol; 2000 Apr; 35(4):586-94. PubMed ID: 10774790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between bleeding time and antithrombotic effect of platelet-suppressive agents in rat experimental model.
    Suehiro A; Oura Y; Ueda M; Kakishita E
    Res Commun Chem Pathol Pharmacol; 1994 Feb; 83(2):157-63. PubMed ID: 8202629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of 1,5-benzothiazepine derivatives having a l-cis and d-cis configuration in anesthetized dogs.
    Kaburaki M; Inoue H; Doi H; Yasuhara M; Narita H
    Biol Pharm Bull; 1998 Jan; 21(1):50-5. PubMed ID: 9477168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. W1, a Novel Oral Antiplatelet Agent With Less Resistance Than Clopidogrel.
    Ge P; Du L; Han C; Li H; Feng Y; Han J; Wang Z; Xiong L; Yuan M; Liu Y
    J Cardiovasc Pharmacol; 2017 Feb; 69(2):110-117. PubMed ID: 27930430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Z-335, a new thromboxane A(2) receptor antagonist, prevents arterial thrombosis induced by ferric chloride in rats.
    Tanaka T; Sato R; Kurimoto T
    Eur J Pharmacol; 2000 Aug; 401(3):413-8. PubMed ID: 10936501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.